March 14, 2006

Dynogen Pharmaceuticals has initiated a Phase II trial of DDP225 in patients with chronic functional vomiting (CFV) and the first patients have been dosed. This trial is a randomized, double-blinded, placebo-controlled study that is assessing multiple symptom-based endpoints. The trial is being conducted at multiple U.S. sites.

CFV is the second clinical indication for DDP225, an orally-active compound that targets two key pathways that control the gastrointestinal (GI) system. Dynogen initiated a Phase II trial for DDP225 in patients with diarrhea-predominant irritable bowel syndrome (IBS-d) in October 2005.

DDP225 is both a noradrenaline reuptake inhibitor and a serotonin Type 3 receptor antagonist. Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the gastrointestinal system. The unique combination of noradrenaline reuptake inhibition and serotonin antagonism in one orally delivered compound represents a novel approach to treating IBS-d and other functional GI diseases.